Author + information
- Perwaiz M. Meraj,
- Rajkumar Doshi,
- Bhavitha George,
- Amitkumar Patel and
- Rajiv Jauhar
Background: The utilization of bivalirudin in patients with non-acute coronary syndromes (N-ACS) gained popularity due to studies demonstrating its superiority over unfractionated heparin (UFH).
Methods: 9895 patients from January 2011- April 2016 were selected from our multicenter CathPCI registry. Adjunctive GpIIbIIIa was given at the discretion of the operator. The primary outcome of in hospital all-cause mortality rates with other secondary outcomes included bleeding and myocardial infarction (MI) were assessed.
Results: No baseline differences existed between the groups after performing adjusted analysis. After multivariate analysis, MI was demonstrated to be significantly higher in the bivalirudin group, while all other outcomes were similar.
Conclusions: Among N-ACS patients, only MI was found to be higher in the bivalirudin arm, while mortality and bleeding were similar. This group comprises a more stable cohort of patients where the presumed benefit of bivalirudin did not exist. This real-world cohort of more stable patients utilizing modern day pharmacotherapy will likely not benefit from bivalirudin during PCI.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Antithrombotic Therapy in Ischemic Heart Disease
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1252-305
- 2017 American College of Cardiology Foundation